Benzinga | Dec 10, 2021 07:36AM EST

TG Therapeutics Recaps Schedule Of Data Presentations At American Society Of Hematology Meeting Dec. 11-13

TG Therapeutics, Inc. (NASDAQ:TGTX), today recapped the schedule of data presentations at the upcoming 63rd American Society of Hematology (ASH) annual meeting and exposition, to be held December 11 -- 14, 2021, virtually and also live at the Georgia World Congress Center in Atlanta, Georgia.

ASH Presentation Details:

Oral Presentations:

Oral Presentation Title: The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial

* Session Date/Time: Saturday, December 11, 2021 / 10:00 AM ET

* Session Name: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy in Low Grade Lymphoma

* Room: Georgia World Congress Center, A411-A412

* Lead Author: Julio Chavez, MD, MS, Moffitt Cancer Center, Tampa, FL

Oral Presentation Title: Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

* Session Date/Time: Sunday, December 12, 2021 / 5:30 PM ET

* Session Name: 626. Aggressive Lymphomas Prospective Therapeutic Trials: Novel Agents and Combinations

* Room: Georgia World Congress Center, Thomas Murphy Ballroom 1-2

* Lead Author: John Burke, MD, Rocky Mountain Cancer Centers / US Oncology Research, Aurora, CO

Oral Presentation Title: A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach

* Session Date/Time: Sunday, December 12, 2021 / 10:30 AM ET

* Session Name: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological I

* Room: Georgia World Congress Center, B401-B402

* Lead Author: Lindsey E. Roeker, MD, CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY

Poster Presentations:

Poster Presentation Title: The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies

* Date/Time: Saturday, December 11, 2021 / 5:30 PM - 7:30 PM ET

* Session Name: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I

* Location: Georgia World Congress Center, Hall B5

* Lead Author: Chan Y. Cheah, MBBS, DMSc, Linear Clinical Research, Nedlands, Australia; Medical School, University of Western Australia, Perth, Australia; and Department of Haematology, Sir Charles Gairdner Hospital, Perth, Australia

Poster Presentation Title: Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial

* Date: Monday, December 13, 2021 / 6:00 PM - 8:00 PM

* Session Name: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III Location: Georgia World Congress Center, Hall B5

* Lead Author: Javier Pinilla-Ibarz, MD, Lymphoma Section Head, Director of Immunotherapy, Malignant Hematology Division at the H. Lee Moffitt Cancer Center in Tampa, Florida

Poster Presentation Title: Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

* Date/Time: Monday, December 13, 2021 / 6:00 PM - 8:00 PM

* Session Name: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III

* Location: Georgia World Congress Center, Hall B5

* Lead Author: Ryan Jacobs, MD, Department of Hematology, Lymphoma Division, Assistant Professor of Medicine, Levine Cancer Institute/Atrium Health, Charlotte, NC

Abstracts are now publicly available via the ASH meeting website at www.hematology.org. Final presentations will be accessible at the above dates/times via the publications page of TG corporate website at http://tgtxinc.com/publications.cfm.